Table 3.
Profile of patients attempting treatment-free remission.
| Overall group | Successful | Unsuccessful | |
|---|---|---|---|
| Number | 12 | 9 | 3 |
| Median age at diagnosis in years (range) | 51 (29–66) | 50 (29–66) | 53 (45–59) |
| Median age at discontinuation in years (range) | 63 (44–82) | 63 (44–82) | 61 (52–67) |
| Gender, n (%) | |||
| Males | 3 (25) | 3 (33) | 0 |
| Female | 9 (75) | 6 (67) | 3 (100) |
| Sokal score, n (%) | |||
| Low | 6 (50) | 5 (56) | 1 (33) |
| Intermediate | 1 (8) | 1 (11) | N/A |
| High | 3 (25) | 1 (11) | 2 (67) |
| Indeterminate | 2 (17) | 2 (22) | N/A |
| Median time of follow-up in months (range) | 12 (8–23) | 12 (8–23) | 12 (11–14) |
| TKI at discontinuation, n (%) | |||
| Imatinib | 11 (92) | 8 (89) | 3 (100) |
| Nilotinib | 1 (8) | 1 (11) | 0 |
| Reasons for TKI discontinuation, n (%) | |||
| Shared∗ | 12 (100) | 9 (75) | 3 (25) |
| Toxicity | 4 (33) | 2 (17) | 2 (17) |
| Median total duration of TKI in months (range) | 133 (87–192) | 137 (87–192) | 96 (87–97) |
| Median time to DMR in months (range) overall | 39 (13–89) | 42 (13–89) | 28 (13–54) |
| MR4 (n − 2) | 72 (54–89) | 89 | 54 |
| MR4.5 (n − 10) | 32 (13–61) | 36 (13–61) | 15 (13−17) |
| Median duration of DMR in months (range) overall | 87 (33–148) | 99 (33–148) | 70 (43–82) |
| MR4 (n − 2) | 40 (37–43) | 37 | 43 |
| MR4.5 (n − 10) | 95 (33–148) | 99 (33–148) | 76 (70–82) |
TKI: tyrosine kinase inhibitor; DMR: deep molecular response; TFR: treatment-free remission; shared decision∗: agreement between treating physician and patient to discontinue TKI therapy.